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The Takeaway © Mosbacher Institute 
The effect of the COVID-19 pandemic on global value chains 
has been pervasive. An all-time-high demand for ventila-
tors, personal protective equipment such as masks and 
gowns, medicines, and other essential health supplies col-
lided with supply shortages.1 Stringent lockdowns enforced 
by different countries at different times led to severe conse-
quences for industrial supply chains.  
As the pandemic spread, few countries have been resilient 
enough to cope well with the pace of transformed supply and 
demand requirements. Many who aligned themselves to out-
sourced manufacturing became dependent on other countries 
for medical supplies. The pandemic reopens key questions:  
 How should firms outsource?  
 How important are costs?  
 How should national-level policies guide firm-level out-
sourcing?  
WHAT’S THE TAKEAWAY? 
 
The COVID-19 pandemic has 
led to severe supply shortages 
in many areas.  
 
These demands could not be 
met by outsourced supply 
sources outside the United 
States that were originally 
meant to lower costs. 
 
The United States must 
develop resilient 
manufacturing capabilities in 
areas critical to national 
interest.  
2 In this policy brief, I explain how firms and 
countries need to critically evaluate their up-
stream supply chains and how public policy 
should support creating domestic core manu-
facturing capabilities that can help mitigate the 
effects of disasters.  
WHY DO FIRMS OUTSOURCE?  
The rationale for outsourcing is rooted in ac-
cess to raw materials, manpower, production 
capacity, and capabilities (like specialized prod-
uct development, design, and innovation). Out-
sourcing may happen when a firm lacks manu-
facturing capability (e.g., knowledge of how to 
produce an input) or capacity (e.g., scale neces-
sary to meet rising demand). Outsourcing is 
also useful when products are widely available. 
It does not make sense for an automobile firm 
to make its own nuts and bolts, even if it can do 
so. Overall, outsourcing can help leverage the 
capabilities of suppliers to provide an enhanced 
offering to the market—fast and at low cost.  
The nature of outsourcing, however, changes 
over time. Suppliers need to customize designs 
and products to specific buyer’s requirements, 
and this often requires suppliers to develop 
new capabilities. Often, buyers participate in 
the development process of these capabilities, 
working closely with suppliers, providing tech-
nical support, and helping produce products 
with better quality at lesser cost. Over time, 
suppliers learn to make the product better—
reducing defects and improving process effi-
ciency.2 As more time goes by and as competi-
tive pressures continue, buyers and suppliers 
seek to reduce costs further. For this, suppliers 
move to control product design and inputs—
selecting the suppliers of components and raw 
materials—to lower production costs and in-
crease manufacturing reliability. This transition 
usually results in suppliers becoming even bet-
ter than the buyer was (at one time) at making 
the product. Meanwhile, the buyer forgets their 
former capabilities, in many cases losing con-
trol over the entire operation.  
My work with an automotive firm in France is 
instructive. Thirty years ago the Knorr Bremse 
(KB) plant was a vertically integrated entity. 
The component design, foundry operations, 
machining operations, and assembly of the final 
product were all done in house. The designers 
had direct access to foundry operations and 
were in close touch with the raw material sup-
pliers, so they knew about the raw material and 
the way it interacted with the performance of 
the final product. The sourcing department had 
less knowledge about how the foundry, machin-
ing, or assembly operated, since most of the 
work was done in house. As time went by, KB 
focused on its design and assembly competen-
cies. Foundry and machining operations were 
outsourced. Currently, operations at KB include 
only design and assembly. The sourcing depart-
ment developed competencies in developing 
and using machining suppliers. The design de-
partment outsourced a lot of design work relat-
ed to foundry and machining to suppliers who 
were doing the same work for other buyers.  
A problem arose when the foundry operations 
of some major castings were going to be shifted 
to China to reduce cost. KB discovered that they 
no longer understood the intricacies of the 
foundry operations. Those competencies had 
been eroded over time as KB acquired ma-
chined components from suppliers, who in turn 
sourced components from established found-
ries. KB found it extremely difficult to certify 
the foundry operations in China. KB had to 
transfer an experienced individual (an old tim-
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er) from its R&D division to purchasing and 
send him to China to establish the new foundry!  
RETHINKING OUTSOURCING 
In the case of COVID-19, unprecedented re-
quirements in many areas could not be met by 
outsourced manufacturing systems. Many in-
dustries, including pharmaceuticals (pharma), 
machinery, automation,3 and automotive,4 ex-
perienced demand and supply shocks. Many of 
these firms had limited insight into what occurs 
at their vendors, and specifically what happens 
beyond their direct vendors. If an upstream 
vendor’s operations were compromised, firms 
had no readily-available alternative.  
To understand the public policy linkages of out-
sourcing in global value chains, let us look at 
pharma. The United States produces very few 
drugs, and by a rough estimate over 80 percent 
of the active pharmaceutical ingredients (APIs), 
even for these drugs, are outsourced (mostly 
from China).5 The problem of having little in-
sight into pharma supply chains is critical and 
widespread. Even the FDA does not know how 
the sourcing of APIs stands.6 Countries like In-
dia that produce many generic drugs, also use 
APIs from China.7  
We have seen reactions on some fronts: the 
United States ramped up production of masks, 
ventilators, and test-kits in the wake of the pan-
demic. GM and Ford developed new ventilator 
manufacturing capabilities. Similarly, in India 
national PPE production capacity has increased 
from practically nothing to more than 500,000 
per day.  
Public policy needs to support resilience in 
global value chains. There are three steps to 
this. First, it is important to identify critical are-
as where a loss of capabilities due to outsourc-
ing could occur. Pharma, defense, medical sup-
plies, machine tools, automation, and communi-
cation may be some of these areas. Criticality 
refers to the risks involved in losing control and 
being ill-equipped for disasters such as COVID-
19 or other natural and political disasters. Sec-
ond, there should be plans deployed for creat-
ing core capabilities in these selected areas, fo-
cusing on creating flexibility through multiple 
local and offshore manufacturing bases. Capa-
bility refers to quickly responding to disrup-
tions by either in-house manufacturing or by 
leveraging alternate suppliers. Third, it is im-
portant to assess how new technologies such as 
robotics and automation can help reduce the 
cost-differentials in manufacturing by combin-
ing resources such as labor and capital to pro-
duce high-quality products at lower costs.  
Firms need to realize that organizational sub-
systems and processes related to suppliers are 
usually focused on the firm and its immediate 
boundary. Firms should try to establish sourc-
ing hubs8 and map the material flow within a 
firm’s supply network to identify critical com-
ponents, understand the technologies involved, 
map lead times for supply of these components, 
and evaluate inventory levels. The supply net-
work needs to be mapped right up to the raw 
material suppliers to have transparency on 
supplies. Once mapped, the supply network can 
be analyzed to develop more flexible sourcing 
by using multiple levers: having geographically 
uncorrelated supply sources (local as well as 
offshore), having a mix of fast versus slow sup-
pliers, and having parallel sources (multiple 
suppliers with the same or very similar capabil-
ities).  
The idea is not to develop huge, vertically inte-
grated firms. However, black-box outsourcing 
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where the parent firm loses all control (and 
more critically, all knowledge) of the out-
sourced activity and related products in its val-
ue chain, may not be an optimal policy. Black-
box outsourcing may, over time, erode the ca-
pabilities of the parent firms—capabilities that 
may be extremely valuable at the national level, 
like the ability to deliver high quality 
healthcare to the citizens. Our work suggests 
that supply chain managers and policy makers 
have systematically underestimated the value 
that they can add by establishing a minimum 
level of control over outsourced activities in 
global supply chains. Such control, where R&D 
scientists, engineers and production workers 
can work together with local inputs can also 
help drive innovation in manufacturing.  
FINAL REMARK 
The global value chain related lesson learned 
from the COVID-19 episode is important: pan-
demics can affect manufacturing in several geo-
graphical locations simultaneously worldwide 
and can affect an individual nation’s surge ca-
pacity to deliver essential supplies to its popu-
lation. Going forward, this lesson should criti-
cally affect thoughts on manufacturing strategy 
and low-cost based outsourcing. We should see 
a sustained push towards development of resil-
ient national manufacturing capabilities in are-
as critical to national interests.  
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